List of works - Laura Villani

Adipose-derived Mesenchymal Stem Cells (ASCs) may favour breast cancer recurrence via HGF/c-Met signaling.

scientific article published on February 2014

Anaemia characterises patients with myelofibrosis harbouring Mpl mutation.

scientific article published in May 2007

Characteristics and clinical correlates of MPL 515W>L/K mutation in essential thrombocythemia

scientific article published on 2 June 2008

Constitutive STAT5 phosphorylation in CD34+ cells of patients with primary myelofibrosis: Correlation with driver mutation status and disease severity

scientific article published on 01 August 2019

EZH2 mutational status predicts poor survival in myelofibrosis.

scientific article published on 14 September 2011

Endothelial colony-forming cells from patients with chronic myeloproliferative disorders lack the disease-specific molecular clonality marker

scientific article published on 23 July 2009

Evaluation of the bioactive and total transforming growth factor β1 levels in primary myelofibrosis.

scientific article published on 30 August 2010

Evidence that prefibrotic myelofibrosis is aligned along a clinical and biological continuum featuring primary myelofibrosis

scientific article

Functional and genetic aberrations of in vitro-cultured marrow-derived mesenchymal stromal cells of patients with classical Philadelphia-negative myeloproliferative neoplasms

scientific article published on 12 March 2014

High frequency of endothelial colony forming cells marks a non-active myeloproliferative neoplasm with high risk of splanchnic vein thrombosis

scientific article

Increased plasma nicotinamide phosphoribosyltransferase is associated with a hyperproliferative phenotype and restrains disease progression in MPN-associated myelofibrosis.

scientific article

JAK2 46/1 haplotype predisposes to splanchnic vein thrombosis-associated BCR-ABL negative classic myeloproliferative neoplasms.

scientific article published on 3 September 2011

JAK2 V617F genotype is a strong determinant of blast transformation in primary myelofibrosis

scientific article

JAK2 V617F mutational status predicts progression to large splenomegaly and leukemic transformation in primary myelofibrosis.

scientific article published on 21 August 2007

JAK2 exon 14 skipping in patients with primary myelofibrosis: a minor splice variant modulated by the JAK2-V617F allele burden

scientific article published on 24 January 2015

JAK2(V617F) allele burden ⩾50% is associated with response to ruxolitinib in persons with MPN-associated myelofibrosis and splenomegaly requiring therapy.

scientific article published on 29 February 2016

MPL and JAK2 exon 12 mutations in patients with the Budd-Chiari syndrome or extrahepatic portal vein obstruction

scientific article published on 01 April 2008

No association between the XPD Lys751Gln (rs13181) polymorphism and disease phenotype or leukemic transformation in primary myelofibrosis.

scientific article published on 28 May 2013

Plasma sIL-2Rα levels are associated with disease progression in myelofibrosis with JAK2V617F but not CALR mutation

scientific article published on 11 February 2020

Primary myelofibrosis: Older age and high JAK2V617F allele burden are associated with elevated plasma high-sensitivity C-reactive protein levels and a phenotype of progressive disease.

scientific article published on 7 June 2017

Reduced frequency of circulating CD4+CD25brightCD127lowFOXP3+ regulatory T cells in primary myelofibrosis

scientific article published on 16 August 2016

Serum hepcidin: a novel diagnostic tool in disorders of iron metabolism

scientific article published on December 2009

Spleen endothelial cells from patients with myelofibrosis harbor the JAK2V617F mutation.

scientific article

The spleen of patients with myelofibrosis harbors defective mesenchymal stromal cells

scientific article

Tie2 Expressing Monocytes in the Spleen of Patients with Primary Myelofibrosis

scientific article

List of works by Laura Villani

Adipose-derived Mesenchymal Stem Cells (ASCs) may favour breast cancer recurrence via HGF/c-Met signaling.

Anaemia characterises patients with myelofibrosis harbouring Mpl mutation.

Characteristics and clinical correlates of MPL 515W>L/K mutation in essential thrombocythemia

Constitutive STAT5 phosphorylation in CD34+ cells of patients with primary myelofibrosis: Correlation with driver mutation status and disease severity

EZH2 mutational status predicts poor survival in myelofibrosis.

Endothelial colony-forming cells from patients with chronic myeloproliferative disorders lack the disease-specific molecular clonality marker

Evaluation of the bioactive and total transforming growth factor β1 levels in primary myelofibrosis.

Evidence that prefibrotic myelofibrosis is aligned along a clinical and biological continuum featuring primary myelofibrosis

Functional and genetic aberrations of in vitro-cultured marrow-derived mesenchymal stromal cells of patients with classical Philadelphia-negative myeloproliferative neoplasms

High frequency of endothelial colony forming cells marks a non-active myeloproliferative neoplasm with high risk of splanchnic vein thrombosis

Increased plasma nicotinamide phosphoribosyltransferase is associated with a hyperproliferative phenotype and restrains disease progression in MPN-associated myelofibrosis.

JAK2 46/1 haplotype predisposes to splanchnic vein thrombosis-associated BCR-ABL negative classic myeloproliferative neoplasms.

JAK2 V617F genotype is a strong determinant of blast transformation in primary myelofibrosis

JAK2 V617F mutational status predicts progression to large splenomegaly and leukemic transformation in primary myelofibrosis.

JAK2 exon 14 skipping in patients with primary myelofibrosis: a minor splice variant modulated by the JAK2-V617F allele burden

JAK2(V617F) allele burden ⩾50% is associated with response to ruxolitinib in persons with MPN-associated myelofibrosis and splenomegaly requiring therapy.

MPL and JAK2 exon 12 mutations in patients with the Budd-Chiari syndrome or extrahepatic portal vein obstruction

No association between the XPD Lys751Gln (rs13181) polymorphism and disease phenotype or leukemic transformation in primary myelofibrosis.

Plasma sIL-2Rα levels are associated with disease progression in myelofibrosis with JAK2V617F but not CALR mutation

Primary myelofibrosis: Older age and high JAK2V617F allele burden are associated with elevated plasma high-sensitivity C-reactive protein levels and a phenotype of progressive disease.

Reduced frequency of circulating CD4+CD25brightCD127lowFOXP3+ regulatory T cells in primary myelofibrosis

Serum hepcidin: a novel diagnostic tool in disorders of iron metabolism

Spleen endothelial cells from patients with myelofibrosis harbor the JAK2V617F mutation.

The spleen of patients with myelofibrosis harbors defective mesenchymal stromal cells

Tie2 Expressing Monocytes in the Spleen of Patients with Primary Myelofibrosis